Nuveen LLC Invests $8.77 Million in Organon & Co. $OGN

Key Points

• Nuveen LLC acquired 589,186 shares of Organon & Co., valued at approximately $8.77 million, during the first quarter, representing about 0.23% of the company's total shares.
• Organon & Co. recently reported a quarterly earnings per share of $1.00, surpassing estimates, but revenue for the quarter was down 0.8% year-over-year at $1.59 billion.
• The company's dividend of $0.02 per share will be paid in September, yielding 0.8%, with a current payout ratio of 2.97%.

Nuveen LLC purchased a new position in shares of Organon & Co. (NYSE:OGN - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 589,186 shares of the company's stock, valued at approximately $8,773,000. Nuveen LLC owned approximately 0.23% of Organon & Co. at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of OGN. Raymond James Financial Inc. purchased a new stake in shares of Organon & Co. during the 4th quarter worth approximately $4,194,000. Canada Pension Plan Investment Board lifted its stake in Organon & Co. by 465.8% in the 4th quarter. Canada Pension Plan Investment Board now owns 21,500 shares of the company's stock valued at $321,000 after buying an additional 17,700 shares in the last quarter. GeoWealth Management LLC purchased a new stake in Organon & Co. in the 4th quarter valued at approximately $41,000. Dimensional Fund Advisors LP lifted its stake in Organon & Co. by 23.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 3,284,408 shares of the company's stock valued at $48,999,000 after buying an additional 629,191 shares in the last quarter. Finally, Stifel Financial Corp lifted its stake in Organon & Co. by 71.8% in the 4th quarter. Stifel Financial Corp now owns 405,528 shares of the company's stock valued at $6,051,000 after buying an additional 169,447 shares in the last quarter. Hedge funds and other institutional investors own 77.43% of the company's stock.

Organon & Co. Stock Up 2.3%

Organon & Co. stock traded up $0.22 during midday trading on Friday, hitting $9.40. 4,579,414 shares of the company were exchanged, compared to its average volume of 4,767,843. The company's fifty day moving average price is $9.61 and its 200-day moving average price is $11.25. The company has a market cap of $2.44 billion, a PE ratio of 3.49, a price-to-earnings-growth ratio of 0.84 and a beta of 0.60. The company has a debt-to-equity ratio of 11.98, a current ratio of 1.65 and a quick ratio of 1.13. Organon & Co. has a fifty-two week low of $8.01 and a fifty-two week high of $22.67.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.00 EPS for the quarter, topping the consensus estimate of $0.94 by $0.06. The firm had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.Organon & Co.'s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. On average, research analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 11th. Investors of record on Friday, August 15th will be given a dividend of $0.02 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.08 annualized dividend and a yield of 0.9%. Organon & Co.'s payout ratio is 2.97%.

Analyst Ratings Changes

A number of research firms recently issued reports on OGN. BNP Paribas raised Organon & Co. to a "strong-buy" rating in a research note on Thursday, May 22nd. Morgan Stanley reduced their target price on Organon & Co. from $15.00 to $10.00 and set an "equal weight" rating on the stock in a research note on Monday, May 5th. Evercore ISI lowered Organon & Co. from an "outperform" rating to an "inline" rating in a research note on Friday, May 2nd. Finally, Piper Sandler reduced their target price on Organon & Co. from $24.00 to $18.00 and set an "overweight" rating on the stock in a research note on Thursday, May 15th. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $18.00.

About Organon & Co.

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.